Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline
05:30pm, Tuesday, 03'rd Mar 2026
The deal would provide ‘certainty' for Moderna's vaccine portfolio.
Moderna Stock Jumps 10% After Hours: Here's Why
04:55pm, Tuesday, 03'rd Mar 2026
Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement.
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
04:46pm, Tuesday, 03'rd Mar 2026
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
04:26pm, Tuesday, 03'rd Mar 2026
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
04:22pm, Tuesday, 03'rd Mar 2026
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Cir
The Market Isn’t Flat. It’s Rotating – And AI Is the Trigger
12:00am, Tuesday, 03'rd Mar 2026
AI is driving a massive stock market rotation. Why software stocks are falling - and hard assets are suddenly winning.
Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash
04:28pm, Monday, 02'nd Mar 2026
Moderna ( MRNA ) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50.
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
08:50am, Monday, 02'nd Mar 2026
Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.
These Dividend ETFs Pay More Than 10-Year Treasury Bonds
08:40am, Monday, 02'nd Mar 2026
If you purchase a 10-year U.S. Treasury bond, you'll get an annual yield of around 4%.
Moderna, Inc. $MRNA Shares Purchased by Banco Santander S.A.
05:00am, Saturday, 28'th Feb 2026
Banco Santander S.A. raised its stake in Moderna, Inc. (NASDAQ: MRNA) by 22.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned
Moderna's Covid-Flu Vaccine Recommended for Approval in EU
07:23am, Friday, 27'th Feb 2026
The recommendation from regulators paves the way for the shot's approval in the European Union at a time the company is facing scrutiny in the U.S.
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive
